Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s40001-021-00490-1 http://scihub22266oqcxt.onion/10.1186/s40001-021-00490-1 33573699!7877333!33573699     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Med+Res 2021 ; 26 (1): 20 Nephropedia Template TP {{tp|p=33573699|t=2021. Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial |pdf=|usr=}}{{33573699}} gab.com Text Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial JO: Eur J Med Res http://www.kidney.de/pget.php?&tw=1&pmid=33573699 #FOAvip BACKGROUND: Vitamin C is an essential water-soluble nutrient that functions as a key antioxidant and has been proven to be effective for boosting immunity. In this study, we aimed to assess the efficacy of adding high-dose intravenous vitamin C (HDIVC) to the regimens for patients with severe COVID-19 disease. METHODS: An open-label, randomized, and controlled trial was conducted on patients with severe COVID-19 infection. The case and control treatment groups each consisted of 30 patients. The control group received lopinavir/ritonavir and hydroxychloroquine and the case group received HDIVC (6 g daily) added to the same regimen. RESULTS: There were no statistically significant differences between two groups with respect to age and gender, laboratory results, and underlying diseases. The mean body temperature was significantly lower in the case group on the 3rd day of hospitalization (p = 0.001). Peripheral capillary oxygen saturations (SpO(2)) measured at the 3rd day of hospitalization was also higher in the case group receiving HDIVC (p = 0.014). The median length of hospitalization in the case group was significantly longer than the control group (8.5 days vs. 6.5 days) (p = 0.028). There was no significant difference in SpO(2) levels at discharge time, the length of intensive care unit (ICU) stay, and mortality between the two groups. CONCLUSIONS: We did not find significantly better outcomes in the group who were treated with HDIVC in addition to the main treatment regimen at discharge. Trial registration irct.ir (IRCT20200411047025N1), April 14, 2020. Twit Text FOAVip Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial ????Eur J Med Res http://www.kidney.de/pget.php?&tw=1&pmid=33573699 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33573699 #FOAvip English Wikipedia <ref>{{Cite pmid|33573699}}</ref> Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial #MMPMID33573699 JamaliMoghadamSiahkali S; Zarezade B; Koolaji S; SeyedAlinaghi S; Zendehdel A; Tabarestani M; Sekhavati Moghadam E; Abbasian L; Dehghan Manshadi SA; Salehi M; Hasannezhad M; Ghaderkhani S; Meidani M; Salahshour F; Jafari F; Manafi N; Ghiasvand F Eur J Med Res 2021[Feb]; 26 (1): 20 PMID33573699show ga BACKGROUND: Vitamin C is an essential water-soluble nutrient that functions as a key antioxidant and has been proven to be effective for boosting immunity. In this study, we aimed to assess the efficacy of adding high-dose intravenous vitamin C (HDIVC) to the regimens for patients with severe COVID-19 disease. METHODS: An open-label, randomized, and controlled trial was conducted on patients with severe COVID-19 infection. The case and control treatment groups each consisted of 30 patients. The control group received lopinavir/ritonavir and hydroxychloroquine and the case group received HDIVC (6 g daily) added to the same regimen. RESULTS: There were no statistically significant differences between two groups with respect to age and gender, laboratory results, and underlying diseases. The mean body temperature was significantly lower in the case group on the 3rd day of hospitalization (p = 0.001). Peripheral capillary oxygen saturations (SpO(2)) measured at the 3rd day of hospitalization was also higher in the case group receiving HDIVC (p = 0.014). The median length of hospitalization in the case group was significantly longer than the control group (8.5 days vs. 6.5 days) (p = 0.028). There was no significant difference in SpO(2) levels at discharge time, the length of intensive care unit (ICU) stay, and mortality between the two groups. CONCLUSIONS: We did not find significantly better outcomes in the group who were treated with HDIVC in addition to the main treatment regimen at discharge. Trial registration irct.ir (IRCT20200411047025N1), April 14, 2020. |*COVID-19 Drug Treatment[MESH] |Antiviral Agents/administration & dosage/*therapeutic use[MESH] |Ascorbic Acid/*administration & dosage/therapeutic use[MESH] |Body Temperature[MESH] |Female[MESH] |Humans[MESH] |Hydroxychloroquine/therapeutic use[MESH] |Intensive Care Units[MESH] |Length of Stay[MESH] |Lopinavir/therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Oxygen/blood[MESH] |Respiratory Distress Syndrome/drug therapy/virology[MESH] |Ritonavir/therapeutic use[MESH]Safety and effectiveness of high-dose vitamin C in patients with COVID(epmc).pdf DeepDyve Pubget Overpricing